1. Search Result
Search Result
Results for "

hypertrophic

" in MedChemExpress (MCE) Product Catalog:

27

Inhibitors & Agonists

4

Natural
Products

4

Recombinant Proteins

5

Isotope-Labeled Compounds

4

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0573
    Propranolol hydrochloride
    Maximum Cited Publications
    44 Publications Verification

    Adrenergic Receptor Bacterial Cardiovascular Disease Infection Neurological Disease Metabolic Disease Cancer
    Propranolol hydrochloride is a nonselective and BBB-permeableβ-adrenergic receptor (βAR) antagonist, has high affinity for the β1AR and β2AR with Ki values of 1.8 nM and 0.8 nM, respectively. Propranolol hydrochloride inhibits [ 3H]-DHA binding to rat brain membrane preparation with an IC50 of 12 nM. Propranolol hydrochloride is used for study of hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy .
    Propranolol hydrochloride
  • HY-B0573B
    Propranolol
    Maximum Cited Publications
    44 Publications Verification

    Adrenergic Receptor Bacterial Cardiovascular Disease Infection Neurological Disease Metabolic Disease Cancer
    Propranolol is a nonselective and BBB-permeable β-adrenergic receptor (βAR) antagonist, has high affinity for the β1AR and β2AR with Ki values of 1.8 nM and 0.8 nM, respectively . Propranolol inhibits [ 3H]-DHA binding to rat brain membrane preparation with an IC50 of 12 nM . Propranolol is used for the study of hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy .
    Propranolol
  • HY-139465
    Aficamten
    3 Publications Verification

    CK-274; CK-3773274

    Myosin Cardiovascular Disease
    Aficamten (CK-274) is a potent cardiac myosin inhibitor with an IC50 of 1.4 μM. Aficamten can be used for the research of hypertrophic cardiomyopathy (HCM) .
    Aficamten
  • HY-N0738
    Stachydrine hydrochloride
    5+ Cited Publications

    NF-κB Endogenous Metabolite Cardiovascular Disease Cancer
    Stachydrine hydrochloride is the major active constituent of Leonurus artemisia, which is a potential therapy for cardiovascular diseases . Stachydrine can inhibit the NF-κB signal pathway. Anti-hypertrophic activities .
    Stachydrine hydrochloride
  • HY-159821

    CK-4021586; CK-586

    Myosin Cardiovascular Disease
    Ulacamten (CK-4021586; CK-586) is an orally active cardiac myosin inhibitor and an inhibitor of the double-headed cardiac heavy meromyosin (HMM)ATPase (excluding single-headed myosin subfragment-1), with an EC50 of 2.9 μM. Ulacamten regulates cardiac myosin, reduces excessive myocardial contractility, and alleviates left ventricular outflow tract obstruction. Ulacamten increases the left ventricular short-axis systolic internal diameter, inhibits dobutamine-induced exacerbation of obstruction, and exerts only a mild reducing effect on left ventricular systolic function. Ulacamten also inhibits the fractional shortening of the short axis without altering calcium transients. Ulacamten shows good safety and tolerability in purpose-bred cats with naturally occurring obstructive hypertrophic cardiomyopathy .
    Ulacamten
  • HY-143248
    KR-39038
    1 Publications Verification

    G Protein-coupled Receptor Kinase (GRK) HDAC Cardiovascular Disease
    KR-39038 is an orally active and potent GRK5 (G protein-coupled receptor kinase 5) inhibitor, with an IC50 of 0.02 μM. KR-39038 significantly inhibits angiotensin II-induced cellular hypertrophy through suppression of HDAC5 pathway in neonatal cardiomyocytes. KR-39038 shows profound anti-hypertrophic effects and improved cardiac function. KR-39038 can be used for heart failure research .
    KR-39038
  • HY-B0573S1

    Adrenergic Receptor Neurological Disease Endocrinology
    Propranolol-d7 (ring-d7) is the deuterium labeled Propranolol hydrochloride. Propranolol hydrochloride is a nonselective β-adrenergic receptor (βAR) antagonist, has high affinity for the β1AR and β2AR with Ki values of 1.8 nM and 0.8 nM, respectively . Propranolol hydrochloride inhibits [3H]-DHA binding to rat brain membrane preparation with an IC50 of 12 nM . Propranolol hydrochloride is used for study of hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy .
    Propranolol-d7 (ring-d7)
  • HY-B0573BS

    Adrenergic Receptor Cardiovascular Disease Neurological Disease Endocrinology
    Propranolol-d7 is the deuterium labeled Propranolol. Propranolol is a nonselective β-adrenergic receptor (βAR) antagonist, has high affinity for the β1AR and β2AR with Ki values of 1.8 nM and 0.8 nM, respectively . Propranolol inhibits [3H]-DHA binding to rat brain membrane preparation with an IC50 of 12 nM . Propranolol is used for the study of hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy .
    Propranolol-d7
  • HY-B0573S

    Adrenergic Receptor Cardiovascular Disease Neurological Disease Endocrinology
    Propranolol-d7 (hydrochloride) is a deuterium labeled Propranolol hydrochloride. Propranolol hydrochloride is a nonselective β-adrenergic receptor (βAR) antagonist, has high affinity for the β1AR and β2AR with Ki values of 1.8 nM and 0.8 nM, respectively . Propranolol hydrochloride inhibits [3H]-DHA binding to rat brain membrane preparation with an IC50 of 12 nM . Propranolol hydrochloride is used for the study of hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy .
    Propranolol-d7 hydrochloride
  • HY-B0573R

    Reference Standards Adrenergic Receptor Bacterial Neurological Disease Endocrinology Cancer
    Propranolol (hydrochloride) (Standard) is the analytical standard of Propranolol (hydrochloride). This product is intended for research and analytical applications. Propranolol hydrochloride is a nonselective β-adrenergic receptor (βAR) antagonist, has high affinity for the β1AR and β2AR with Ki values of 1.8 nM and 0.8 nM, respectively . Propranolol hydrochloride inhibits [ 3H]-DHA binding to rat brain membrane preparation with an IC50 of 12 nM . Propranolol hydrochloride is used for study of hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy .
    Propranolol hydrochloride (Standard)
  • HY-172424

    Myosin Cardiovascular Disease
    Delocamten is the inhibitor for cardiac myosin with an IC50 of 1.1 μM. Delocamten can be used in researchs of hypertrophic cardiomyopathy, left ventricular hypertrophy and diastolic dysfunction .
    Delocamten
  • HY-176850

    Myosin Cardiovascular Disease
    Myosin-IN-2 (Example 16) is a Myosin ATPase inhibitor with a IC50 of 1.06  μM. Myosin-IN-2 can be used for heart diseases like hypertrophic cardiomyopathy (HCM) research .
    Myosin-IN-2
  • HY-176914

    Ferroptosis Myosin Cardiovascular Disease Inflammation/Immunology
    Myosin-IN-3 (Compound 4-1) is a pyrimidine ketone derivative. Myosin-IN-3 exhibits significant anti ferroptotic activity (IC50 = 3.11 μM) while possessing myosin (IC50 = 3.09 μM) inhibitory activity and antioxidant activity (DPPH EC50 = 23.17 μM; MDA EC50 = 55.34 μM). Myosin-IN-3 can be used for research on heart conditions such as hypertrophic cardiomyopathy .
    Myosin-IN-3
  • HY-161608

    Myosin Cardiovascular Disease
    Myosin modulator 1 (Compound B141) is a modulator for myosin, that inhibits ATPase in rabbits psoas, porcine atria and in porcine ventricle, with IC25s of 0.42, 0.13 and 3.09 μM, respectively. Myosin modulator 1 regulates systolic cardiac performance in Sprague Dawley rats .
    Myosin modulator 1
  • HY-161609

    Myosin Cardiovascular Disease
    Myosin modulator 2 (Compound B172) is a modulator for myosin, that inhibits ATPase in rabbits psoas, porcine atria and in porcine ventricle, with IC25s of 2.013, 2.94 and 20.93 μM, respectively. Myosin modulator 2 regulates systolic cardiac performance in Sprague Dawley rats .
    Myosin modulator 2
  • HY-150040

    G Protein-coupled Receptor Kinase (GRK) Cardiovascular Disease Cancer
    CCG-273463 is a potent, selective and covalent GRK5 inhibitor with an IC50 value of 8.6 nM. CCG-273463 can be used in the research of heart failure, hypertrophic cardiomyopathy, and cancer .
    CCG-273463
  • HY-152190

    Myosin Cardiovascular Disease
    JB002 is a myosin II inhibitor, with an IC50 of ≤10 μM. JB002 can be used for the research of muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathy .
    JB002
  • HY-161663

    Phosphodiesterase (PDE) Cardiovascular Disease
    Phosphodiesterase-IN-2 (Compound C7) is a selective, orally active inhibitor for phosphodiesterase 10A (PDE10A), with an IC50 of 11.9 nM. Phosphodiesterase-IN-2 improves the stability of liver microsomes, and lowers BBB permeability. Phosphodiesterase-IN-2 exhibits good pharmacokinetic characters, and attenuates isoprenaline (HY-108353)-induced cardiac hypertrophic in mouse models .
    Phosphodiesterase-IN-2
  • HY-152206

    Myosin Neurological Disease
    JB062 is a nonmuscle myosin inhibitor with IC50 values of 1.6, 5.4, and >100 μM for Skeletal muscle myosin, Cardiac muscle myosin, and Smooth muscle myosin II, respectively. JB062 has cytotoxic to human cancer cells but not normal cells. JB062 can be used in research of muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathy .
    JB062
  • HY-107333

    PPAR Metabolic Disease
    Cinoxate is a hypertrophic peroxisome proliferator activating receptor γ (PPARγ) agonist with Ki value of 18.0 μM. Cinoxate can be used to study obesity .
    Cinoxate
  • HY-107333S

    Isotope-Labeled Compounds PPAR Metabolic Disease
    Cinoxate-d3 is deuterium labeled Cinoxate. Cinoxate is a hypertrophic peroxisome proliferator activating receptor γ (PPARγ) agonist with Ki value of 18.0 μM. Cinoxate can be used to study obesity .
    Cinoxate-d3
  • HY-W759845

    CK-274-d3; CK-3773274-d3

    Isotope-Labeled Compounds Myosin Cardiovascular Disease
    Aficamten-d3 (CK-274-d3) is deuterium labeled Aficamten. Aficamten (CK-274) is a potent cardiac myosin inhibitor with an IC50 of 1.4 μM. Aficamten can be used for the research of hypertrophic cardiomyopathy (HCM) .
    Aficamten-d3
  • HY-103484

    IKZF Family Cardiovascular Disease
    GATA4-NKX2-5-IN-1 (Compound 3) dose-dependently inhibits the GATA4–NKX2-5 transcriptional synergy with an IC50 of 3 μM. GATA4-NKX2-5-IN-1 exhibits no activity on the protein kinases involved in the regulation of GATA4 phosphorylation, and it modulates the hypertrophic agonist-induced cardiac gene expression .
    GATA4-NKX2-5-IN-1
  • HY-17681

    Myosin Cardiovascular Disease
    Myosin-IN-5 (example 3) is a selective cardiac myosin inhibitor with an IC50 of 1.5 μM. Myosin-IN-5 shows much less effective in inhibiting skeletal myofibril activity (IC50 of 43.4 μM). Myosin-IN-5 can be used for the study of hypertrophic cardiomyopathy (HCM) and cardiac diseases .
    Myosin-IN-5
  • HY-169241

    Isotope-Labeled Compounds Cardiovascular Disease
    B3 is an isotope-labeled active compound suitable for the study of hypertrophic cardiomyopathy .
    B3
  • HY-W192276

    N-Desisopropylpropranolol

    Drug Metabolite Adrenergic Receptor Cardiovascular Disease Neurological Disease Endocrinology Cancer
    (±)-Desisopropylpropranolol (N-Desisopropylpropranolol) is a metabolite of Propranolol (HY-B0573B). Propranolol is a nonselective β-adrenergic receptor (βAR) antagonist, has high affinity for the β1AR and β2AR with Kis of 1.8 nM and 0.8 nM, respectively. Propranolol inhibits [ 3H]-DHA binding to rat brain membrane preparation with an IC50 of 12 nM. Propranolol is used for the study of hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy .
    (±)-Desisopropylpropranolol
  • HY-103484R

    IKZF Family Reference Standards Cardiovascular Disease
    GATA4-NKX2-5-IN-1 (Standard) is the analytical standard of GATA4-NKX2-5-IN-1 (HY-103484). This product is intended for research and analytical applications. GATA4-NKX2-5-IN-1 (Compound 3) dose-dependently inhibits the GATA4–NKX2-5 transcriptional synergy with an IC50 of 3 μM. GATA4-NKX2-5-IN-1 exhibits no activity on the protein kinases involved in the regulation of GATA4 phosphorylation, and it modulates the hypertrophic agonist-induced cardiac gene expression .
    GATA4-NKX2-5-IN-1 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: